Clinical Trials
22 trialsNCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT02996825 2024-04-02
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT03657966 2021-04-21
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT01610206 2021-02-25
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
Phase 2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT02046421 2018-09-11
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 1 Completed
NCT02275039 2018-04-30
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00434642 2017-08-09
OCEANS
Genentech, Inc.
Phase 3 Completed
NCT00061308 2017-06-09
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00031954 2015-12-23
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
AGO Study Group
Phase 2 Completed
NCT01652794 2015-08-04
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00096993 2015-06-10
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 2 Completed
NCT00267696 2015-04-30
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01196559 2015-02-18
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The Catholic University of Korea
Phase 2 Completed
NCT00004082 2013-06-26
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003358 2013-01-16
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00191646 2011-03-04
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT00217555 2010-09-21
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00191607 2007-01-26
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
Phase 3 Completed